<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104378">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137161</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002066-39</org_study_id>
    <nct_id>NCT02137161</nct_id>
  </id_info>
  <brief_title>Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery</brief_title>
  <acronym>REPEX</acronym>
  <official_title>The Reggio Emilia Study on Bromfenac for Patients With PseudoEXfoliation Syndrome Undergoing Cataract Surgery: the REPEX Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcispedale Santa Maria Nuova-IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcispedale Santa Maria Nuova-IRCCS</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE To evaluate the efficacy of bromfenac ophthalmic solution 0.09% for reducing
      postoperative inflammation in eyes with pseudoexfoliation syndrome (PEX) undergoing cataract
      surgery and receiving standard postoperative eye drops (dexamethasone 0.1% plus tobramycin
      0.3% ophthalmic solution).

      DESIGN Two arms, parallel group, randomized, single center, prospective, phase IV clinical
      trial.

      PARTICIPANTS Sixty-two subjects with PEX and cataract will be sequentially assigned,
      according to a computer-generated randomization list (1:1), to bromfenac (n = 31) or not (n
      = 31).

      INTERVENTION Cataract surgery by means of phacoemulsification and implantation of
      posterior-chamber intraocular lens will be performed by two experienced ophthalmic surgeons.

      Standard Arm: only a standard antibiotic and steroid ophthalmic suspension will be given
      starting the day after the surgery for two weeks, dosed QID for the first week and BID for
      the second week (dexamethasone 0.1% and tobramycin 0.3% eye drops association).

      Experimental Arm: eyes will receive bromfenac BID for two weeks starting the day after
      surgery. Standard post-operative topical antibiotic and steroid will be also given
      concurrently, dosed QID for the first week and BID for the second week (dexamethasone 0.1%
      and tobramycin 0.3% eye drops association).

      Measurements will be carried out at baseline and after one day, 3 days, 1 week and 4 weeks
      from cataract extraction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in anterior chamber inflammation measured by Laser Flare Photometry (photon counts per millisecond)</measure>
    <time_frame>Baseline, Day 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of 30% of anterior chamber inflammation evaluated by Laser Flare Photometry (LFP) in the bromfenac arm when compared to the non-bromfenac arm at postoperative day 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with central macular thickness greater than 300 microns</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>Macular thickness will be evaluated by Spectral Domain Optical Coherence Tomography (SD-OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with best corrected visual acuity equal to 20/20</measure>
    <time_frame>Baseline, Week 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who had no ocular pain</measure>
    <time_frame>Baseline, Day 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Cataract</condition>
  <condition>Pseudoexfoliation Syndrome</condition>
  <arm_group>
    <arm_group_label>Dexamethasone+Tobramycin eye drop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An antibiotic and steroid eye drop association will be given starting the day after the surgery for two weeks, dosed QID for the first week and BID for the second week, to 31 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bromfenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bromfenac eye drops (BID for two weeks starting the day after surgery) plus an antibiotic and steroid eye drop association (QID for the first week and BID for the second week) will be given concurrently to 31 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone+Tobramycin eye drop</intervention_name>
    <description>dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension</description>
    <arm_group_label>Dexamethasone+Tobramycin eye drop</arm_group_label>
    <arm_group_label>Bromfenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromfenac eye drop</intervention_name>
    <description>bromfenac ophthalmic solution 0.09%</description>
    <arm_group_label>Bromfenac</arm_group_label>
    <other_name>Yellox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cataract

          -  pseudoexfoliation syndrome

        Exclusion Criteria:

          -  history of ocular inflammation or trauma

          -  previous intraocular surgery

          -  corneal haze

          -  retinal vascular disease

          -  diabetic retinopathy

          -  variation of the foveal profile at OCT (macular edema, epiretinal membrane)

          -  moderate to severe age related macular degeneration
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Coassin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arcispedale S. Maria Nuova IRCCS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Fontana, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Arcispedale S. Maria Nuova IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Coassin, MD PhD</last_name>
    <phone>00390522296219</phone>
    <email>marco.coassin@asmn.re.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova IRCSS - Ophthalmology</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marco Coassin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Exfoliation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
